New study tests tofacitinib for kids with arthritis

NCT ID NCT07211932

Not yet recruiting Disease control Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test the drug tofacitinib in 58 children with juvenile idiopathic arthritis (JIA) to see if it improves disease control after 12 months. Researchers will use real-world medical records to measure changes in arthritis activity. The goal is to find out if tofacitinib is a helpful treatment option for kids with JIA.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tofacitinib
What this could lead to: If it works, this could show that tofacitinib is an effective option for controlling juvenile idiopathic arthritis in children.
What could go wrong: This is a small, early-stage real-world study with only 58 participants, so results may not apply broadly. Tofacitinib can have side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE IDIOPATHIC ARTHRITIS (JIA)

Contacts and locations

Locations

Corporació Sanitària Parc Taulí de Sabadell

Sabadell, Barcelona, Spain
Hospital Sant Joan de Déu Barcelona

Barcelona, Barcelona, Spain
Hospital de Vilafranca

Vilafranca del Penedès, Barceona, 08720, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.